AG2R LA Mondiale Gestion D Actifs Takes $2.56 Million Position in Becton, Dickinson and Company $BDX

Key Points

• AG2R LA Mondiale Gestion D Actifs has acquired a new stake in Becton, Dickinson and Company, purchasing 11,181 shares valued at approximately $2.56 million.
• Becton, Dickinson reported a 10.4% increase in revenue year-over-year, totaling $5.51 billion, and earnings per share of $3.68 for the last quarter.
• The company declared a quarterly dividend of $1.04 per share, reflecting an annualized dividend yield of 2.2%, with a payout ratio of 74.82%.

AG2R LA Mondiale Gestion D Actifs bought a new position in Becton, Dickinson and Company (NYSE:BDX - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 11,181 shares of the medical instruments supplier's stock, valued at approximately $2,561,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Saudi Central Bank purchased a new stake in shares of Becton, Dickinson and Company during the first quarter valued at approximately $26,000. Smallwood Wealth Investment Management LLC purchased a new stake in shares of Becton, Dickinson and Company during the first quarter valued at approximately $27,000. REAP Financial Group LLC boosted its stake in shares of Becton, Dickinson and Company by 75.3% during the fourth quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock valued at $29,000 after purchasing an additional 55 shares during the period. Alpine Bank Wealth Management purchased a new stake in shares of Becton, Dickinson and Company during the first quarter valued at approximately $29,000. Finally, Cornerstone Planning Group LLC boosted its stake in shares of Becton, Dickinson and Company by 341.4% during the first quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier's stock valued at $29,000 after purchasing an additional 99 shares during the period. Hedge funds and other institutional investors own 86.97% of the company's stock.

Becton, Dickinson and Company Price Performance

NYSE BDX traded up $1.02 during trading hours on Thursday, reaching $188.59. The company's stock had a trading volume of 446,493 shares, compared to its average volume of 2,542,055. The firm's 50-day moving average price is $187.20 and its 200-day moving average price is $190.92. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 1 year low of $163.33 and a 1 year high of $251.99. The company has a market capitalization of $54.05 billion, a price-to-earnings ratio of 33.96, a PEG ratio of 1.50 and a beta of 0.27.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.40 by $0.28. The business had revenue of $5.51 billion for the quarter, compared to analysts' expectations of $5.50 billion. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The company's revenue for the quarter was up 10.4% on a year-over-year basis. During the same period in the prior year, the firm earned $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, equities research analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th will be given a $1.04 dividend. This represents a $4.16 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend is Monday, September 8th. Becton, Dickinson and Company's dividend payout ratio is 74.82%.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Wall Street Zen raised Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Piper Sandler reaffirmed a "neutral" rating and issued a $200.00 price target (up previously from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Morgan Stanley raised their price target on Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an "overweight" rating in a research note on Monday, August 11th. Citigroup lowered Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and dropped their price target for the stock from $217.00 to $185.00 in a research note on Thursday, May 22nd. Finally, Argus raised their price target on Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday. Four research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $213.30.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Claire Fraser sold 917 shares of the company's stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the transaction, the director owned 22,226 shares of the company's stock, valued at $4,167,375. This represents a 3.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Michael David Garrison sold 1,185 shares of the company's stock in a transaction on Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the sale, the executive vice president owned 4,887 shares of the company's stock, valued at $881,077.23. This represents a 19.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 2,965 shares of company stock worth $551,536 in the last ninety days. 0.36% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.